Review article: The relevance of portal pressure and other risk factors in acute gastro-oesophageal variceal bleeding

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue SUPPL. 3, 2004, Pages 8-15

  Dell'Era, A ^a   Bosch, J ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCULATION; CONFERENCE PAPER; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; ESOPHAGUS VARICES BLEEDING; HUMAN; LIVER FAILURE; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STOMACH VARICES; THICKNESS; VEIN DIAMETER; VEIN RUPTURE; VEIN TONE;

BACTERIAL INFECTIONS; BLOOD COAGULATION DISORDERS; BLOOD TRANSFUSION; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPERTENSION, PORTAL; LIVER FAILURE; PORTAL PRESSURE; RISK FACTORS;

EID: 4644245880     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02109.x     Document Type: Conference Paper

References (76)

1. Wiest R, Groszmann RJ. Nitric oxide and portal hypertension its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 1999; 19: 411-26.
2. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000; 32 (Suppl. 1): 141-56.
3. Sakurabayashi S, Sezai S, Yamamoto Y, Hirano M, Oka H. Embolization of portal-systemic shunts in cirrhotic patients with chronic recurrent hepatic encephalopathy. Cardiovasc Intervent Radiol 1997; 20: 120-4.
4. Bellis L. Berzigotti A, Abraldes JG, et al. Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology 2003; 37: 378-84.
5. Luca A, Garcia-Pagan JC. Bosch J, et al. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology 1997; 112: 1284-9.
6. Garcia-Pagan JC, Feu F, Castells A, et al. Circadian variations of portal pressure and variceal hemorrhage in patients with cirrhosis. Hepatology 1994; 19: 595-601.
7. Garcia-Pagan JC, Santos C, Barbera JA, et al. Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. Gastroenterology 1996; 111: 1300-6.
8. Luca A, Cirera I, Garcia-Pagan JC, et al. Hemodynamic effects of acute changes in intra-abdominal pressure in patients with cirrhosis. Gastroenterology 1993; 104: 222-7.
9. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage [see comments]. Gastroenterology 1990; 99: 1401-7.
10. Feu F, Garcia-Pagan JC, Bosch J, et al Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346 (8982): 1056-9.
11. Villanueva C, Minana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345: 647-55.
12. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan J, Rodes J, Bosch J. Hemodynamic response to pharmacologic treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37: 902-8.
13. Mahl TC, Groszmann RJ. Pathophysiology of portal hypertension and variceal bleeding. Surg Clin North Am 1990; 70: 251-66.
14. Polio J, Groszmann RJ. Hemodynamic factors involved in the development and rupture of esophageal varices: a pathophysiologic approach to treatment. Semin Liver Dis 1986; 6: 318-31.
15. Rigau J, Bosch J, Bordas JM, et al. Endoscopic measurement of variceal pressure in cirrhosis: correlation with portal pressure and variceal hemorrhage. Gastroenterology 1989; 96: 873-80.
16. Escorsell A, Bordas JM, Feu F, et al. Endoscopic assessment of variceal Volume and wall tension in cirrhotic patients: effects of pharmacological therapy. Gastroenterology 1997; 113: 1640-6.
17. Escorsell A, Bordas JM, Castaneda B, et al. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology 2000; 31: 1061-7.
18. Nevens F. Non-invasive variceal pressure measurements: validation and clinical implications. Verh K Acad Geneeskd Belg 1996; 58: 413-37.
19. Bureau C, Peron JM, Alric L, et al. 'A la carte' treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 2002; 36: 1361-6.
20. Bosch J, Bordas JM, Rigau J, et al. Noninvasive measurement of the pressure of esophageal varices using an endoscopic gauge: comparison with measurements by variceal puncture in patients undergoing endoscopic sclerotherapy. Hepatology 1986; 6: 667-72.
21. Viallet A, Marleau D, Huet M, et al. Hemodynamic evaluation of patients with intrahepatic portal hypertension. Relationship between bleeding varices and the portohepatic gradient. Gastroenterology 1975; 69: 1297-300.
22. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985; 5: 419-24.
23. Casado M, Bosch J, Garcia-Pagan JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998; 114: 1296-303.
24. de Franchis R, Primignani M. Natural history of portal hypertension in patients with cirrhosis. Clin Liver Dis 2001; 5: 645-63.
25. Burroughs AK, Mezzanotte G, Phillips A, Mccormick PA, Mcintyre N. Cirrhotics with variceal hemorrhage. the importance of the time interval between admission and the start of analysis for survival and rebleeding rates. Hepatology 1989; 9: 801-7.
26. Okuda K, Kono K, Ohnishi K, et al Clinical study of eighty-six cases of idiopathic portal hypertension and comparison with cirrhosis with splenomegaly. Gastroenterology 1984; 86: 600-10.
27. Niec. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices [see comments]. N Engl J Med 1988; 319: 983-9.
28. Merkel C, Zoli M, Siringo S, et al. Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to validate and improve the North Italian Endoscopic Club (NIEC) index. Am J Gastroenterol 2000; 95: 2915-20.
29. D'Amico G, de Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003; 38: 599-612.
30. Vinel JP, Cassigneul J, Levade M, Voigt JJ. Pascal JP. Assessment of short-term prognosis after variceal bleeding in patients with alcoholic cirrhosis by early measurement of portohepatic gradient. Hepatology 1986; 6: 116-7.
31. Ready JB, Robertson AD, Goff JS. Rector WG Jr. Assessment of the risk of bleeding from esophageal varices by continuous monitoring of portal pressure. Gastroenterology 1991; 100: 1403-10.
32. Moitinho E, Escorsell A, Bandi JC, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999; 117: 626-31.
33. Castaneda B, Debernardi-Venon W, Bandi JC. et al. The role of portal pressure in the severity of bleeding in portal hypertensive rats. Hepatology 2000; 31: 581-6.
34. Garcia-Villarreal L, Martinez-Lagares F, Sierra A, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal rebleeding after recent variceal hemorrhage. Hepatology 1999; 29: 27-32.
35. Morales J, Moitinho E, Abraldes JG, Fernandez M, Bosch J. Effects of the Via vasopressin agonist F-180 on portal hypertension-related bleeding in portal hypertensive rats. Hepatology 2003; 38: 1378-83.
36. Levacher S, Letoumelin P, Pateron D, Biaise M, Lapandry C, Pourriat JL. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995; 346 (8979): 865-8.
37. Avgerinos A, Nevens F, Raptis S, Fevery J. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet 1997; 350 (9090): 1495-9.
38. Banares R, Albillos A, Rincon D, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 2002; 35: 609-15.
39. de Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 2000; 33: 846-52.
40. Chau TN, Chan YW, Patch D, Tokunaga S, Greenslade L, Burroughs AK. Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. Gut 1998; 43: 267-71.
41. de Franchis R, Arcidiacono PG, Carpinelli L, et al. Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. New Italian Endoscopic Club. Hepatol 1993; 18: 1102-7.
42. Smith O, Hazlehurst G, Brozovic B, et al. Impact of aprotinin on blood transfusion requirements in liver transplantation. Transfus Med 1993; 3: 97-102.
43. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997; 113(6): 1930-7.
44. Ejlersen E, Melsen T, Ingerslev J, Andreasen RB, Vilstrup H. Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol 2001; 36: 1081-5.
45. Thabut D, de Franchis R, Bendtsen F, et al. Efficacy of activated recombinant factor VII (rFVIIa; Novoseven) in cirrhotic patients with upper gastrointestinal bleeding: a randomised placebo-controlled double-blind multicenter trial. J Hepatol 2003; 38 (Suppl. 2): 13A.
46. Goulis J, Patch D, Burroughs AK. Bacterial infection in the pathogenesis of variceal bleeding [see comments]. Lancet 1999; 353 (9147): 139-42.
47. Poynard T, Cales P. Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group N Engl J Med 1991; 324: 1532-8.
48. Navasa M, Rimola A, Rodés J. Bacterial infections in liver disease. Semin Liver Dis 1997; 17: 323-33.
49. Pannen BH, Bauer M, Zhang JX, Robotham JL, Clemens MG. A time-dependent balance between endothelins and nitric oxide regulating portal resistance after endotoxin. Am J Physiol 1996, 1996; 271: H1953-61.
50. Bakes AT, Howard KM, Miller JE, Olson MS. Endothelin-1 production by hepatic endothelial cells: characterization and augmentation by endotoxin exposure. Am J Physiol 1997; 272: G605-11.
51. Yamamoto S, Burman HP, O'Donnell CP, Cahill PA, Robotham JL. Endothelin causes portal and pulmonary hypertension in porcine endotoxemic shock. Am J Physiol 1997; 272: H1239-49.
52. Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18: 1139-43.
53. Gratton JP, Maurice MC, D'Orleans-Juste P. Characterization of endothelin receptors and endothelin-converting enzyme activity in the rabbit lung. J Cardiovasc Pharmacol 1995; 26 (Suppl. 3): S88-90.
54. Papatheodoridis GV, Patch D, Webster GJ, Brooker J, Barnes E, Burroughs AK. Infection and hemostasis in decompensated cirrhosis: a prospective study using thrombelastography. Hepatology 1999; 29: 1085-90.
55. Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998; 27: 1207-12.
56. Guarner C, Soriano G. Spontaneous bacterial peritonitis. Semin Liver Dis 2001; 17: 203-7.
57. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29: 1655-61.
58. Blaise M, Pateron D, Trinchet JC, Levacher S, Beaugrand M, Pourriat JL. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1994; 20: 34-8.
59. Bernard B, Cadranel JF, Valla D, Escolano S. Jarlier V, Opolon P. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology 1995; 108: 1828-34.
60. Elizalde JI, Moitinho E, Garcia-Pagan JC, et al. Effects of increasing blood hemoglobin levels on systemic hemodynamics of acutely anemic cirrhotic patients. J Hepatol 1998; 29: 789-95.
61. Panes J, Casadevall M, Pique JM, Bosch J, Whittle BJ, Teres J. Effects of acute normovolemic anemia on gastric mucosal blood flow in rats: role of nitric oxide. Gastroenterology 1992; 103: 407-13.
62. Bauer M, Zhang JX, Bauer I, Clemens MG. ET-1 induced alterations of hepatic microcirculation, sinusoidal and extrasinusoidal sites of action. Am J Physiol (Gastrointest Liver Physiol) 1994; 30: G143-9.
63. Kravetz D, Sikuler E, Groszmann RJ. Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood Volume restitution. Gastroenterology 1986; 90: 1232-40.
64. Kravetz D, Bosch J, Arderiu M, Filar PM, Rodes J. Hemodynamic effects of blood Volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: influence of the extent of portal-systemic shunting. Hepatology 1989; 9: 808-14.
65. Koshy A. Sekiyama T, Cereda JM, Hadengue A. Girod C, Lebrec D. Effects of haemorrhage and Volume expansion on portal-systemic collateral vascular resistance in conscious portal hypertensive rats. Clin Sci (Lond) 1990; 78: 193-7
66. Castaneda B, Morales J, Lionetti R, et al. Effects of blood Volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats. Hepatology 2001; 33: 821-5.
67. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332-54.
68. Boyer JL, Chatterjee C. Iber FL, Basu AK. Effect of plasma-Volume expansion on portal hypertension. N Engl J Med 1966; 275: 750-5.
69. Garden OJ, Motyl H, Gilmour WH, Utley RJ, Carter DC. Prediction of outcome following acute variceal haemorrhage. Br J Surg 1985; 72: 91-5.
70. Gatta A, Merkel C, Amodio P, et al. Development and validation of a prognostic index predicting death after upper gastrointestinal bleeding in patients with liver cirrhosis: a multicenter study. Am J Gastroenterol 1994; 89: 1528-36.
71. Graham D, Smith J. The course of patients after variceal hemorrhage. Gastroeneterology 1981; 80: 800-6.
72. Cardenas A, Gines P, Uriz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 2001; 34: 671-6.
73. Vivas S, Rodriguez M, Palacio MA, Linares A, Alonso JL, Rodrigo L. Presence of bacterial infection in bleeding cirrhotic patients is independently associated with early mortality and failure to control bleeding. Dig Dis Sci 2001; 46: 2752-7.
74. Moitinho E, Planas R, Banares R, et al. Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding. J Hepatol 2001; 35: 712-8.
75. Ben Ari Z, Cardin F, Mccormick AP, Wannamethee G, Burroughs AK. A predictive model for failure to control bleeding during acute variceal haemorrhage. J Hepatol 1999; 31: 443-50.
76. Garcia-Pagan JC, Escorsell A, Moitinho E, Bosch J. Influence of pharmacological agents on portal hemodynamics: Basis for its use in the treatment of portal hypertension. Semin Liver Dis 1999; 19: 427-38.